Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms
Diego Cantoni,
Gabriel Siracusano,
Martin Mayora-Neto,
Claudia Pastori,
Tobia Fantoni,
Spyros Lytras,
Cecilia Di Genova,
Joseph Hughes,
on behalf of the Ambulatorio Medico San Luca Villanuova Group,
Lucia Lopalco,
Nigel Temperton
Affiliations
Diego Cantoni
Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham ME4 4TB, UK
Gabriel Siracusano
Division of Immunology, Transplantation and Infectious Disease, Immunobiology of HIV Group, San Raffaele Scientific Institute, 20132 Milan, Italy
Martin Mayora-Neto
Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham ME4 4TB, UK
Claudia Pastori
Division of Immunology, Transplantation and Infectious Disease, Immunobiology of HIV Group, San Raffaele Scientific Institute, 20132 Milan, Italy
Tobia Fantoni
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37129 Verona, Italy
Spyros Lytras
MRC-Centre for Virus Research, University of Glasgow, Glasgow G12 BQQ, UK
Cecilia Di Genova
Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham ME4 4TB, UK
Joseph Hughes
MRC-Centre for Virus Research, University of Glasgow, Glasgow G12 BQQ, UK
on behalf of the Ambulatorio Medico San Luca Villanuova Group
Ambulatorio Medico San Luca Villanuova, Villanuova sul Clisi, 25089 Brescia, Italy
Lucia Lopalco
Division of Immunology, Transplantation and Infectious Disease, Immunobiology of HIV Group, San Raffaele Scientific Institute, 20132 Milan, Italy
Nigel Temperton
Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham ME4 4TB, UK
Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic beginning in 2019, have highlighted the importance of effective vaccines to induce an antibody response with cross-neutralizing activity. COVID-19 vaccines have been rapidly developed to reduce the burden of SARS-CoV-2 infections and disease severity. Cross-protection from seasonal human coronaviruses (hCoVs) infections has been hypothesized but is still controversial. Here, we investigated the neutralizing activity against ancestral SARS-CoV-2 and the variants of concern (VOCs) in individuals vaccinated with two doses of either BNT162b2, mRNA-1273, or AZD1222, with or without a history of SARS-CoV-2 infection. Antibody neutralizing activity to SARS-CoV-2 and the VOCs was higher in BNT162b2-vaccinated subjects who were previously infected with SARS-CoV-2 and conferred broad-spectrum protection. The Omicron BA.1 variant was the most resistant among the VOCs. COVID-19 vaccination did not confer protection against hCoV-HKU1. Conversely, antibodies induced by mRNA-1273 vaccination displayed a boosting in their neutralizing activity against hCoV-NL63, whereas AZD1222 vaccination increased antibody neutralization against hCoV-229E, suggesting potential differences in antigenicity and immunogenicity of the different spike constructs used between various vaccination platforms. These data would suggest that there may be shared epitopes between the HCoVs and SARS-CoV-2 spike proteins.
